Advertisement

Management of Hypertension

  • Eckhart J. BuchmannEmail author
Chapter
  • 1.2k Downloads
Part of the Current Cardiovascular Therapy book series (CCT)

Abstract

High blood pressure affects about 10 % of pregnancies worldwide (Duley 2009), and is the second-most frequent cause of maternal death (Khan et al. 2006). The most serious form of pregnancy hypertension is pre-eclampsia, a progressive multisystem disorder only curable by delivery of the infant. Pre-eclampsia is found in about 2–8 % of pregnancies (Duley 2009), with 5–8 % of pre-eclamptic women in less-developed countries going on to eclamptic convulsions (World Health Organization 2011). Other complications of pre-eclampsia include intracerebral haemorrhage, pulmonary oedema, liver rupture, placental abruption, fetal growth restriction, and HELLP (haemolysis, elevated liver enzymes, low platelets) syndrome.

Keywords

Severe Hypertension Fetal Growth Restriction Magnesium Sulphate Gestational Hypertension HELLP Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Abalos E, Duley L, Steyn DW, Henderson-Smart DJ. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2007;1:CD002252.Google Scholar
  2. Ahmed A. New insights into the etiology of preeclampsia: identification of key elusive factors for the vascular complications. Thromb Res. 2011;127 Suppl 3:S72–5.PubMedCrossRefGoogle Scholar
  3. American Academy of Pediatrics Committee on, Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics. 2001;108:776–89.Google Scholar
  4. American College of Obstetricians and Gynecologists. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol. 2002;99:159–67.CrossRefGoogle Scholar
  5. Beardmore KS, Morris JM, Gallery ED. Excretion of antihypertensive medication into human breast milk: a systematic review. Hypertens Pregnancy. 2002;21:85–95.PubMedCrossRefGoogle Scholar
  6. Bullo M, Tschumi S, Bucher BS, Bianchetti MG, Simonetti GD. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review. Hypertension. 2012;60:444–50.PubMedCrossRefGoogle Scholar
  7. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009;33:130–7.PubMedCrossRefGoogle Scholar
  8. Duley L, Henderson-Smart DJ, Meher S. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev. 2006;3:CD001449.Google Scholar
  9. Duley L, Gulmezoglu AM, Henderson-Smart DJ, Chou D. Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. Cochrane Database Syst Rev. 2010;11:CD000025.Google Scholar
  10. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:1106–10.PubMedCrossRefGoogle Scholar
  11. James MF. Magnesium in obstetrics. Best Pract Res Clin Obstet Gynaecol. 2010;24:327–37.PubMedCrossRefGoogle Scholar
  12. Khan KS, Wojdyla D, Say L, Gulmezoglu AM, Van Look PF. World Health Organisation analysis of causes of maternal death: a systematic review. Lancet. 2006;367:1066–74.PubMedCrossRefGoogle Scholar
  13. Koopmans CM, Bijlenga D, Groen H, Vijgen SM, Aarnoudse JG, Bekedam DJ, van den Berg PP, de Boer K, Burggraaff JM, Bloemenkamp KW, Drogtrop AP, Franx A, de Groot CJ, Huisjes AJ, Kwee A, van Loon AJ, Lub A, Papatsonis DN, van der Post JA, Roumen FJ, Scheepers HC, Willekes C, Mol BW, van Pampus MG, HYPITAT Study Group. Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks’ gestation (HYPITAT): a multicentre, open-label randomised controlled trial. Lancet. 2009;374:979–88.PubMedCrossRefGoogle Scholar
  14. Lecarpentier E, Morel O, Fournier T, Elefant E, Chavatte-Palmer P, Tsatsaris V. Statins and pregnancy: between supposed risks and theoretical benefits. Drugs. 2012;72:773–88.PubMedCrossRefGoogle Scholar
  15. Magee LA, Abalos E, von Dadelszen P, Sibai B, Easterling T, Walkinshaw S, CHIPS Study Group. How to manage hypertension in pregnancy effectively. Br J Clin Pharmacol. 2011;72:394–401.PubMedCrossRefGoogle Scholar
  16. Martin Jr JN. Milestones in the quest for best management of patients with HELLP syndrome (microangiopathic hemolytic anemia, hepatic dysfunction, thrombocytopenia). Int J Gynaecol Obstet. 2013;121:202–7.PubMedCrossRefGoogle Scholar
  17. Meher S, Abalos E, Carroli G. Bed rest with or without hospitalisation for hypertension during pregnancy. Cochrane Database Syst Rev. 2005;4:CD003514.Google Scholar
  18. Nij Bijvank SW, Duvekot JJ. Nicardipine for the treatment of severe hypertension in pregnancy: a review of the literature. Obstet Gynecol Surv. 2010;65:341–7.PubMedCrossRefGoogle Scholar
  19. Pennington KA, Schlitt JM, Jackson DL, Schulz LC, Schust DJ. Preeclampsia: multiple approaches for a multifactorial disease. Dis Model Mech. 2012;5:9–18.PubMedCrossRefGoogle Scholar
  20. Podymov T, August P. Antihypertensive drugs in pregnancy. Semin Nephrol. 2011;31:70–85.CrossRefGoogle Scholar
  21. Powe CE, Levine RJ, Karumanchi SA. Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation. 2011;123:2856–69.PubMedCrossRefGoogle Scholar
  22. Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2006;3:CD004454.Google Scholar
  23. Society for Maternal-Fetal Medicine, Sibai B. Evaluation of management of severe pre-eclamsia before 34 weeks gestatation. Am J Obstet Gynecol. 2011;205:191–8.PubMedCrossRefGoogle Scholar
  24. SOMANZ Guidelines for the management of hypertensive disorders of pregnancy 2008. Society of Obstetric Medicine of Australia and New Zealand. 2008.Google Scholar
  25. The Collaborative Eclampsia Trial Group. Which anticonvulsant for women with eclampsia? Evidence from the Collaborative Eclampsia Trial. Lancet. 1995;345:1455–63.Google Scholar
  26. The Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). ESC guidelines on the management of cardiovascular diseases during pregnancy. Eur Heart J. 2011;32:3147–97.CrossRefGoogle Scholar
  27. World Health Organization. WHO recommendations for prevention and treatment of pre-eclampsia and eclampsia. Geneva: World Health Organization. 2011.Google Scholar
  28. Woudstra DM, Chandra S, Hofmeyr GJ, Dowswell T. Corticosteroids for HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome in pregnancy. Cochrane Database Syst Rev. 2010;9:CD008148.Google Scholar
  29. Young BC, Levine RJ, Karumanchi SA. Pathogenesis of preeclampsia. Annu Rev Pathol. 2010;5:173–92.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2014

Authors and Affiliations

  1. 1.Department of Obstetrics and GynaecologyUniversity of the WitwatersrandJohannesburgSouth Africa

Personalised recommendations